COVID-19 a planned trial for Ruxolitinib (Jakavi) to treat patients

[Mazcd]

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with severe/very severe COVID-19 illness. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Condition or disease: severe/very severe COVID-19 illness. Intervention/treatment: Drug Ruxolitinib (Jakavi)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. For general information, Learn About Clinical Studies.

clinicaltrials.gov/ct2/abou...

Criteria for inclusion and exclusion and further details about this trial

Full details for this trial can be found here… clinicaltrials.gov/ct2/show...

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04337359

To learn more about this study, you or your doctor may contact the study research staff.

[Linda_Alexander]

Hi Maz

Just wondering as they are trailing Ruxolitinib to help those with severe Covid 19, could it be that those of us already on Ruxolitinib may not be so affected by the virus as was first thought.

Or is that just wishful thinking on my behalf. Has anyone on the forum who takes Ruxolitinib had Covid 19 and survived? Would it depend on the strength of the tablets you are on as I noted the trail says 5mg.

Hope everyone is keeping safe and well

[Mazcd Partner MPNVoice in reply to Linda_Alexander]

Hi Linda, it is too early to know this. Best wishes, Maz